JP Morgan Maintains Overweight on AbbVie, Raises Price Target to $300
JP Morgan analyst Chris Schott maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $300.
Share
Why It Matters
A big bank analyst thinks AbbVie stock looks good and raised their price goal. This suggests the analyst sees reasons to feel confident about the company's future.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.